Abstract:
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced today that Michael J. Heller has presented results demonstrating nanofabrication applications of the company's NanoChip® technology at the LabAutomation 2007 conference in Palm Springs, Calif. Heller was a co-founder of Nanogen along with current chairman and CEO Howard Birndorf in 1993 and is now a professor of bioengineering at the University of California, San Diego.

Heller's presentation described the use of Nanogen's proprietary electronic "pick and place" technology to direct the assembly of nanoparticles in a rapid and cost-effective manner. His research team has used Nanogen's NanoChips and NC400 instrument to build multi-layered structures of nanoparticles by electronically directing the components to targeted positions on a microarray template.

"Completed structures can later be ‘popped off' the template by several simple procedures. It's a unique approach to the assembly of nanoparticles into more complex structures," said Heller. "Potential applications include the production of micro-scale biosensors that may ultimately be used in the body to monitor diseases.

"There are also many uses outside of biomedical and environmental monitoring such as the manufacture of photovoltaic devices, fuel cells and batteries," he added. "It is currently very expensive to produce these devices and materials because integration of many nano and microscale components has to be accomplished. Nanogen's technology, which allows for a ‘bottom up' integrated assembly, has the potential to make nanomanufacture relatively easy and cheap."

Nanogen has an extensive portfolio of intellectual property relating to integrated assembly of molecular structures through the use of electric field microfabrication technology. For licensing opportunities, contact Nanogen.

Heller's presentation was titled, "Automated Combinatorial Process for Fabrication of Multilayered Nanoparticle Structures." Additional information about the conference, sponsored by the Association for Laboratory Automation, is available at: http://labautomation.org/LA/LA07/index.php .

####

About Nanogen, Inc. Nanogen’s advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip®400 electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen’s ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogen’s website at www.nanogen.com.

Nanogen Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.